Skip to main content Back to Top
Advertisement

11/8/2019

Hydroxyzine Pamoate Oral Capsules

Products Affected - Description

    • Vistaril oral capsule, Pfizer, 25 mg, bottle, 100 count, NDC 00069-5410-66
    • Vistaril oral capsule, Pfizer, 50 mg, bottle, 100 count, NDC 00069-5420-66
    • Hydroxyzine pamoate oral capsule, Amneal, 25 mg, bottle, 100 count, NDC 00115-1803-01
    • Hydroxyzine pamoate oral capsule, Heritage, 25 mg, bottle, 100 count, NDC 14539-0674-01
    • Hydroxyzine pamoate oral capsule, Heritage, 25 mg, bottle, 500 count, NDC 14539-0674-05
    • Hydroxyzine pamoate oral capsule, Heritage, 50 mg, bottle, 100 count, NDC 14539-0675-01
    • Hydroxyzine pamoate oral capsule, Heritage, 50 mg, bottle, 500 count, NDC 14539-0675-05
    • Hydroxyzine pamoate oral capsule, Teva, 100 mg, bottle, 100 count, NDC 00555-0324-02
    • Hydroxyzine pamoate oral capsule, Teva, 25 mg, bottle, 100 count, NDC 00555-0323-02
    • Hydroxyzine pamoate oral capsule, Teva, 25 mg, bottle, 500 count, NDC 00555-0323-04
    • Hydroxyzine pamoate oral capsule, Teva, 50 mg, bottle, 100 count, NDC 00555-0302-02
    • Hydroxyzine pamoate oral capsule, Teva, 50 mg, bottle, 500 count, NDC 00555-0302-04

Reason for the Shortage

    • Amneal did not provide a reason for the shortage.
    • Heritage did not provide a reason for the shortage.
    • Mylan discontinued hydroxyzine pamoate capsules in May 2019.
    • Pfizer did not provide a reason for the shortage.
    • Rising discontinued hydroxyzine pamoate capsules.
    • Sandoz has hydroxyzine pamoate capsules available.
    • Teva has hydroxyzine pamoate capsules available.

Available Products

    • Hydroxyzine pamoate oral capsule, Amneal, 25 mg, bottle, 500 count, NDC 00115-1803-02
    • Hydroxyzine pamoate oral capsule, Amneal, 50 mg, bottle, 100 count, NDC 00115-1804-01
    • Hydroxyzine pamoate oral capsule, Amneal, 50 mg, bottle, 500 count, NDC 00115-1804-02
    • Hydroxyzine pamoate oral capsule, Sandoz, 25 mg, bottle, 100 count, NDC 00185-0674-01
    • Hydroxyzine pamoate oral capsule, Sandoz, 25 mg, bottle, 500 count, NDC 00185-0674-05
    • Hydroxyzine pamoate oral capsule, Sandoz, 50 mg, bottle, 100 count, NDC 00185-0615-01
    • Hydroxyzine pamoate oral capsule, Sandoz, 50 mg, bottle, 500 count, NDC 00185-0615-05

Estimated Resupply Dates

    • Amneal has hydroxyzine pamoate 25 mg capsules in 100 count bottles on intermittent back order and the company is releasing product as it becomes available.
    • Heritage has hydroxyzine pamoate 25 mg capsules in 100 count and 500 count and 50 mg capsules in 100 count and 500 count on allocation.
    • Teva has hydroxyzine pamoate 25 mg capsules in 100 count and 500 count and 50 mg capsules in 100 count and 500 count on back order and the company estimates a release date of mid-November 2019.
    • Pfizer has Vistaril 25 mg and 50 mg capsules in 100 count bottles on back order and the company estimates a release date of late-November 2019 for the 25 mg capsules and cannot estimate a release date for the 50 mg capsules.

Updated

Updated November 8, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 14, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins